Table 2.

Select clinical trials of everolimus (RAD-001) in glioblastoma.

Study (year)	Phase	Dose (n)	PR (%)	OS	PFS	Ref.
Kreisl et al. (2009)	Pilot	DE PO (n = 2); 70 mg/week PO (n = 20)	14	Median: 5.8 months; 6-month: N/A	Median: 2.6 months; 6-month: 4.5%	[18]
Chinnaiyan et al. (2013)	I	2.5 mg/day PO (n = 8); 5 mg /day PO (n = 9); 10 mg/day PO (n = 8)	N/A	Median: N/A; 6-month: 100%	Median: N/A; 6-month: N/A	[19]
Sarkaria et al. (2011)	I	30 mg/week PO (n = 6); 50 mg/week PO (n = 6); 70 mg/week PO (n = 6)	11	Median: N/A; 6-month: N/A	Median: N/A; 6-month: N/A	[22]
Mason et al. (2012)	I	2.5 mg/day PO (n = 5); 5 mg/day PO (n = 15); 10 mg/day PO (n = 12)	11	Median: N/A; 6-month: N/A	Median: N/A; 6-month: N/A	[21]
Hainsworth et al. (2012)	II	10 mg/day PO (n = 57)	61	Median: 13.9 months; 6-month: N/A	Median: 11.3 months; 6-month: 73%	[20]

DE: Dose escalation; N/A: Not assessed; OS: Overall survival; PFS: Progression-free survival; PO: Per oral; PR: Partial response.